Stocktoria
ImmunityBio, Inc. IBRX
ImmunityBio, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 | $605,000 | $2.2M | $47,000 | $45,000 | $44,000 |
| R&D expense | — | $190.1M | $232.4M | $248.1M | $196.0M | $139.5M | $112.0M | $55.7M | $42.0M | $29.2M |
| SG&A expense | — | $168.8M | $129.6M | $102.7M | $135.3M | $71.3M | $46.5M | $42.7M | $57.1M | $95.4M |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M | -$330.3M | -$220.9M | -$156.3M | -$98.4M | -$99.1M | -$124.5M |
| Interest expense | $60.9M | $114.6M | $128.8M | $63.5M | $14.8M | $9.1M | $5.9M | — | $618,000 | $66,000 |
| Income tax | -$135,000 | $0 | -$40,000 | $34,000 | $9,000 | -$1.8M | -$105,000 | -$503,000 | -$493,000 | -$572,000 |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M | -$221.9M | -$157.8M | -$96.2M | -$96.4M | -$120.8M |
| EPS (diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | — | — | — |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M | -$171.7M | -$152.1M | -$63.4M | -$48.8M | -$38.6M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M | -$173.4M | -$156.4M | -$76.5M | -$83.6M | -$45.2M |
| Cash & equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M | $34.9M | $75.8M | $16.8M | $23.9M | $8.1M |
| Inventory | $910,000 | $8.3M | $0 | — | — | — | — | — | — | — |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M | $221.4M | $143.1M | $181.9M | $250.4M | $317.5M |
| Total liabilities | $1.0B | $871.1M | $1.1B | $812.2M | $712.8M | $339.9M | $22.4M | $35.9M | $31.6M | $24.1M |
| Shareholders' equity | -$500.5M | -$489.1M | -$587.0M | -$449.8M | -$243.9M | -$119.8M | $120.7M | $146.0M | $218.8M | $293.4M |
Growth · year-over-year · Revenue CAGR 139.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +668.3% | +2270.6% | +159.2% | -74.3% | +54.4% | -72.5% | +4585.1% | +4.4% | +2.3% | -81.4% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.